RecruitingNCT01518400

LIFE Cancer Survivorship Database for Pediatric Cancer

A Research Database for Survivors of Childhood Cancer


Sponsor

Children's Hospital Los Angeles

Enrollment

5,000 participants

Start Date

Feb 1, 2009

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this study is to develop a mechanism for utilizing the comprehensive clinical database of childhood cancer survivors at Childrens Hospital Los Angeles (CHLA) for research purposes. Using clinical information obtained from follow-up visits of childhood cancer survivors, the database will focus on interventions to improve health status and health-related quality of life in childhood cancer survivors. This study allows for establishment and analyses of a research database for LIFE survivors by the investigators listed herein. Over the last three decades, there has been marked improvement in survival following childhood cancer, with 5-year survival rates now approaching 80%. However, the use of cancer therapy at an early age can result in complications that may not be apparent until years later as the child matures. These resulting complications, called late effects, are principally related to the specific therapy employed and the age of the child at the time the therapy was administered. Late effects may affect virtually every body system and substantially impair quality of life. As many as two-thirds of childhood cancer survivors develop at least one late effect as a result of treatment, and approximately one-third have a late effect classified as severe or life threatening.


Eligibility

Inclusion Criteria3

  • Been diagnosed with cancer or similar disease
  • Been diagnosed with cancer at 21 years of age or younger
  • Be currently off treatment and disease free

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Children's Hospital Los Angeles

Los Angeles, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT01518400


Related Trials